SOAT1 Antibody (A-11): sc-136959

SOAT1 Antibody (A-11) is a mouse monoclonal IgG1 antibody that detects SOAT1 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). SOAT1, also known as sterol O-acyltransferase-1 or ACAT1, is a homotetrameric enzyme that plays a crucial role in cellular cholesterol homeostasis by catalyzing the formation of cholesterol esters from cholesterol and long-chain fatty acyl-coenzyme A. This enzymatic activity is particularly important as SOAT1 contributes to the regulation of cholesterol levels within cells, thereby influencing processes such as foam cell formation and the progression of atherosclerosis. The gene encoding human SOAT1 is located on chromosome 1 and is predominantly expressed in the endoplasmic reticulum of various tissues, including the liver, kidney, adrenal glands, and macrophages. SOAT1 localization to the endoplasmic reticulum positions this enzyme to effectively manage cholesterol esterification, which is vital for maintaining lipid homeostasis and preventing the pathological accumulation of lipids that can lead to cardiovascular diseases. Additionally, the development of SOAT inhibitors for atherosclerosis treatment underscores SOAT1′s importance in therapeutic interventions aimed at managing cholesterol-related disorders. anti-SOAT1 antibody (A-11) is an essential tool for researchers investigating the role of cholesterol metabolism in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

SOAT1 Antibody (A-11) References:

1. ACAT1/SOAT1 as a therapeutic target for Alzheimer's disease.  |  Shibuya, Y., et al. 2015. Future Med Chem. 7: 2451-67. PMID: 26669800
2. SOAT1 deficiency attenuates atherosclerosis by regulating inflammation and cholesterol transportation via HO-1 pathway.  |  Wu, N., et al. 2018. Biochem Biophys Res Commun. 501: 343-350. PMID: 29567472
3. Proteomic heterogeneity reveals SOAT1 as a potential biomarker for hepatocellular carcinoma.  |  Khatib, SA. and Wang, XW. 2019. Transl Gastroenterol Hepatol. 4: 37. PMID: 31231704
4. SOAT1 promotes mevalonate pathway dependency in pancreatic cancer.  |  Oni, TE., et al. 2020. J Exp Med. 217: PMID: 32633781
5. SOAT1 is a new prognostic factor of colorectal cancer.  |  Wang, XC., et al. 2022. Ir J Med Sci. 191: 1549-1554. PMID: 34460058
6. SOAT1 enhances lung cancer invasiveness by stimulating AKT-mediated mitochondrial fragmentation.  |  Mo, Y., et al. 2022. Biochem Cell Biol. 100: 68-74. PMID: 34670102
7. Acute ACAT1/SOAT1 Blockade Increases MAM Cholesterol and Strengthens ER-Mitochondria Connectivity.  |  Harned, TC., et al. 2023. Int J Mol Sci. 24: PMID: 36982602
8. A pan-cancer analysis identifies SOAT1 as an immunological and prognostic biomarker.  |  Huang, Y., et al. 2023. Oncol Res. 31: 193-205. PMID: 37304239
9. Ferroptosis sensitization in glioma: exploring the regulatory mechanism of SOAT1 and its therapeutic implications.  |  Sun, S., et al. 2023. Cell Death Dis. 14: 754. PMID: 37980334
10. ACAT1/SOAT1 maintains adipogenic ability in preadipocytes by regulating cholesterol homeostasis.  |  Liu, Q., et al. 2024. J Lipid Res. 65: 100680. PMID: 39481851

The preferred SOAT1 antibody is SOAT1 Antibody (ACAT-1): sc-69836.